ITMN had the option to convert their US interest into a pure royalty. I didn't look at the reworked contract but would imagine that would be their best avenue for further cost cuts. If I were to guess I would say they will wait to hear back from the FDA and decide to do that along with start another Phase 3.
I still haven't written 191 off... but now have no money on it either :-).
Market Data 
Markets 
AI
